Skip to main content

Daclatasvir Dosage

Applies to the following strengths: 90 mg; 30 mg; 60 mg

Usual Adult Dose for Chronic Hepatitis C

60 mg orally once a day

Recommended Regimen and Duration of Therapy:
Genotype 1:


Genotype 3:

Comments:

Use: With sofosbuvir (with or without ribavirin), for the treatment chronic HCV genotype 1 or 3 infection

Renal Dose Adjustments

No adjustment recommended.

Comments:

Liver Dose Adjustments

Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): No adjustment recommended.

Comments:

Dose Adjustments

Coadministration with strong CYP450 3A inhibitors and certain HIV antiviral agents: 30 mg orally once a day
Coadministration with moderate CYP450 3A inducers and nevirapine: 90 mg orally once a day
Coadministration with strong CYP450 3A inducers: Contraindicated

The dose of this drug should not be reduced for side effects.

If sofosbuvir is permanently discontinued, this drug should also be discontinued.

Precautions

US BOXED WARNING:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:

Other Comments

Administration advice:


General:

Patient advice:

Frequently asked questions

More about daclatasvir

Patient resources

Other brands

Daklinza

Professional resources

Other brands

Daklinza

Related treatment guides

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.